{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-24-000010","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.050175+00:00","generated_at":"2026-06-07T03:53:42.429222+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pacira reports preliminary FY2023 revenue of $675.0M, up 1.2% YoY; Q4 EXPAREL sales $143.9M","bullets":["FY2023 total revenue $675.0M vs $666.8M in FY2022, driven by EXPAREL ($538.1M), ZILRETTA ($111.1M), iovera° ($19.7M).","Q4 2023 EXPAREL net sales $143.9M (+4.3% YoY); ZILRETTA $28.7M (+2.5%); iovera° $6.0M (+30%).","ExPAREL full-year average daily volume growth of 5%, offset by lower net selling price from 340B and other contracts.","Company plans to launch EXPAREL in two lower extremity nerve blocks in 2024 and expects NOPAIN Act expansion in 2025.","Preliminary, unaudited figures; complete Q4/FY results with 2024 guidance expected in Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-24-000010","json":"https://secwatch.observer/filing/0001396814-24-000010.json","markdown":"https://secwatch.observer/filing/0001396814-24-000010.md","text":"https://secwatch.observer/filing/0001396814-24-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681424000010/0001396814-24-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681424000010/pcrx-20240104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:53:42.429222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20ad421a45fe91a873bdc56f2eb9719e7f6c2228","claim":"Pacira BioSciences, Inc. reported full-year ended December 31, 2023 results: revenue $675.0 million.","evidence_excerpt":"Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $675.0 million for the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681424000010/0001396814-24-000010-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year ended December 31, 2023"},{"label":"Revenue","value":"$675.0 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"be6e98410e7cd0d726ed1c9685afea087d9e30e1","claim":"Pacira BioSciences, Inc. reported preliminary financial results for fourth quarter ended December 31, 2023.","evidence_excerpt":"On January 4, 2024, Pacira BioSciences, Inc. issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681424000010/0001396814-24-000010-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}